Eloralintide Dosage: Trial Doses, Escalation and 10 mg Vial Units
Reviewed by
Brandon Johnson — Certified Personal Trainer, Nutrition Coach & Peptide Research Consultant
Brandon Johnson is a certified personal trainer, nutrition coach, and peptide research consultant with a background in kinesiology and over 15 years of experience in fitness and wellness. He reviews all PSPeptides educational content for scientific accuracy and practical relevance.
Eloralintide dosage in the 48-week Phase 2 trial ran from 1 mg to 9 mg once weekly, and the fixed 9 mg arm produced a −20.1% body-weight change against −0.4% for placebo, while the slowest escalation (3 mg, then 6 mg, then 9 mg) gave −16.4% with the lowest nausea rate (25.0%) of any arm that reached 9 mg. Those two numbers frame the published record, and this guide sets out the doses, escalation weeks and vial arithmetic behind them.
Eloralintide is Eli Lilly’s investigational amylin receptor agonist and is not approved by the FDA or any other regulator as of October 2026, so every figure below describes what trial protocols did rather than what anyone should do. The same eloralintide dosage levels are the reference points for laboratory work with the single 10 mg lyophilized eloralintide vial from PSPeptides, which is why this guide pairs the trial schedules with units-per-dose tables for that vial.
The eloralintide research guide covers the molecule, its receptor pharmacology and every dataset in sequence; this page stays on dose, schedule and quantity.
Eloralintide Dosage at a Glance
| Parameter | What the published record shows (October 2026) |
|---|---|
| Phase 2 weekly doses (48 weeks, no type 2 diabetes) | 1, 3, 6 and 9 mg fixed; 6→9 mg escalation; 3→6→9 mg escalation |
| Phase 1b weekly doses (12 weeks, no titration) | 1.2, 3, 6 and 12 mg |
| Single doses (Phase 1) | 0.04, 0.12, 0.4, 1.2, 4 and 12 mg |
| Highest weekly dose in any trial | 12 mg (Phase 1b only); highest Phase 2 dose 9 mg |
| Escalation schedules actually used | 6 mg for 20 weeks then 9 mg for 28 weeks; 3 mg for 4 weeks, 6 mg for 4 weeks, then 9 mg for 40 weeks |
| Half-life | 310–366 hours after single doses; about 14 days with weekly dosing; peak-to-trough ratio 1.28–1.38 |
| Time to steady state | Roughly 2 to 2.5 months of weekly dosing |
| Efficacy versus nausea at 9 mg | Fixed 9 mg −20.1% with 33.3% nausea; 3→6→9 mg −16.4% with 25.0% nausea |
| Research vial | Single 10 mg lyophilized vial; 10 mg/mL with 1.0 mL bacteriostatic water, so 1 mg = 10 units |
| Regulatory status | Investigational; Phase 3 doses not disclosed |
Sources: Billings et al., The Lancet 2025; Lilly press release, Nov 6, 2025; Bhattachar et al., Diabetes, Obesity and Metabolism 2026; Briere et al., Molecular Metabolism 2025; Lilly, “What to know about eloralintide.”

Every Eloralintide Dose Studied in Humans
Four human datasets define the eloralintide dosage range. The first-in-human study (Part A of NCT05295940) gave 48 healthy participants single subcutaneous doses between 0.04 and 12 mg, and only the 4 mg and 12 mg cohorts separated from placebo on day 29, at −2.5% and −4.4% against +0.6% (Briere et al., Molecular Metabolism 2025).
Part B of the same program (Bhattachar et al., Diabetes, Obesity and Metabolism 2026) then gave 1.2, 3, 6 or 12 mg once weekly for 12 weeks to 73 participants, with 27 on placebo, without any titration. Phase 2 (Billings et al., The Lancet 2025) narrowed the weekly eloralintide dosage range to 1 to 9 mg over 48 weeks and added the two escalation arms that most later discussion centres on.
| Study | Population and duration | Eloralintide doses | Weight change at end of dosing (placebo) |
|---|---|---|---|
| Phase 1 single dose (Part A, NCT05295940) | 48 healthy adults, mean BMI 27.5; day 29 | 0.04, 0.12, 0.4, 1.2, 4, 12 mg, one injection | 4 mg −2.5%; 12 mg −4.4%; lower doses not different from placebo (+0.6%) |
| Phase 1b multiple dose (Part B) | 100 randomised, three US centres; 12 weeks weekly, no titration | 1.2 mg (n=8), 3 mg (n=6), 6 mg (n=23), 12 mg (n=36) | −2.6%, −8.9%, −8.5%, −11.3% (+0.2%) |
| Phase 2 (NCT06230523) | 263 adults with obesity or overweight, no type 2 diabetes; 48 weeks | 1, 3, 6, 9 mg fixed; 6→9 mg; 3→6→9 mg | −9.5%, −12.4%, −17.6%, −20.1%; 6→9 −19.9%; 3→6→9 −16.4% (−0.4%), efficacy estimand |
| EloraTZP Phase 2b (NCT06603571) | 367 adults with obesity or overweight and type 2 diabetes; 48 weeks | 3, 6, 9 mg alone; 3+5, 6+5, 6+10, 9+15 mg with tirzepatide, as separate weekly injections | Alone −8.2%, −12.3%, −11.1%; combinations −13.2% to −23.3% (−3.0%) |
Sources: Briere et al., Molecular Metabolism 2025; Bhattachar et al., Diabetes, Obesity and Metabolism 2026; Lilly press release, Nov 6, 2025; Billings et al., The Lancet 2025; Lilly press release, Sept 30, 2026.
Two cautions apply to that table. The Phase 1b 3 mg cohort (−8.9%) only looks better than 6 mg (−8.5%) because it held six people, and the EloraTZP eloralintide-alone arms were run in people with type 2 diabetes (T2D), so their lower figures are not a contradiction of Phase 2 (Lilly press release, Sept 30, 2026). Full outcome detail by arm sits in the eloralintide results review.
The Two Phase 2 Escalation Schedules and the Nausea Trade-Off
The Phase 2 escalation weeks are the single most misquoted part of the eloralintide dosage literature, so here they are from the Lancet full text. The 6→9 mg arm (n=24) stayed at 6 mg for 20 weeks and then took 9 mg for the remaining 28 weeks. The 3→6→9 mg arm (n=52) took 3 mg for four weeks, 6 mg for four weeks, and then 9 mg for 40 weeks. A description of “four-week steps for all arms” is wrong.
Set the three eloralintide dosage routes to 9 mg side by side and the trade-off is explicit. Fixed 9 mg from the first week delivered the largest loss, −20.1%, at 33.3% nausea; 6→9 mg reached −19.9% but with 54.2% nausea; and 3→6→9 mg held nausea to 25.0% and vomiting to 1.9% while finishing at −16.4%, the smallest loss of the three, with a higher adverse-event discontinuation rate (11.5%) than fixed 9 mg (7.4%).
| Phase 2 arm | Weekly schedule | Week-48 change (efficacy estimand) | Nausea | Vomiting | Constipation | Fatigue | Stopped for AEs |
|---|---|---|---|---|---|---|---|
| Placebo (n=53) | Placebo throughout | −0.4% | 13.5% | 0% | 6% | 11.5% | 7.7% |
| 1 mg (n=28) | 1 mg, weeks 1–48 | −9.5% | 11.1% | 0% | 15–17% | 0% | 11.1% |
| 3 mg (n=24) | 3 mg, weeks 1–48 | −12.4% | 13.0% | 0% | 15–17% | 13.0% | 0% |
| 6 mg (n=28) | 6 mg, weeks 1–48 | −17.6% | 64.3% | 25.0% | Not reported | 28.6% | 21.4% |
| 9 mg (n=54) | 9 mg, weeks 1–48 | −20.1% | 33.3% | 11.1% | 24.1% | 42.6% | 7.4% |
| 6→9 mg (n=24) | 6 mg weeks 1–20; 9 mg weeks 21–48 | −19.9% | 54.2% | 12.5% | 16.7% | 45.8% | 8.3% |
| 3→6→9 mg (n=52) | 3 mg weeks 1–4; 6 mg weeks 5–8; 9 mg weeks 9–48 | −16.4% | 25.0% | 1.9% | 7.7% | 21.2% | 11.5% |
Source: Lilly press release, Nov 6, 2025 (efficacy estimand); Billings et al., The Lancet 2025 (schedules and adverse-event rates, safety population N=260). Arms are small, so per-arm percentages are noisy.
Lilly’s own summary of the pattern reads: “The most common adverse events were mild to moderate gastrointestinal symptoms and fatigue, which were seen more frequently in the higher dose arms,” with incidence lower under slower escalation and similar to placebo at 1 and 3 mg (Lilly press release, Nov 6, 2025). One wrinkle is diarrhoea, which was highest in the slow arm at 17.3% versus 11.1% on fixed 9 mg and 12.5% on 6→9 mg.
The oddest row is fixed 6 mg: 64.3% nausea, 25.0% vomiting and a 21.4% discontinuation rate, all worse than fixed 9 mg. With 28 people in that arm the most defensible reading is noise rather than a true inverted dose response; per-arm rates carry wide uncertainty throughout the table. The eloralintide side-effects article works through each event class in turn.

Why the Dose Is Weekly: Half-Life, Steady State and Wash-Out
Every eloralintide dosage in every trial was given once a week because the molecule’s C20 fatty diacid binds albumin and stretches its terminal half-life to 310–366 hours, or 12.9–15.3 days, across 0.4–12 mg single doses, with a median Tmax of 72–132 hours; the discovery paper states that this profile “supports once-weekly dosing” (Briere et al. 2025). Repeated weekly dosing in Phase 1b produced an estimated 14-day half-life, “relatively flat” concentrations and a steady-state peak-to-trough ratio of 1.28–1.38.
A 14-day half-life means weekly doses stack for a long time before levels plateau, roughly 2 to 2.5 months, so a 12-week eloralintide dosage protocol reaches steady state only in its final weeks and a 48-week one spends most of its length there. The same kinetics make the exit slow: in Phase 1b, weight effects were still significant 9 to 10 weeks after the last 6 or 12 mg dose (Bhattachar et al. 2026). Our peptide half-life chart ranks eloralintide against other weekly peptides.
Reconstituting the 10 mg Vial: Concentration and Units per Dose
Units are where eloralintide dosage arithmetic goes wrong most often, because a U-100 insulin syringe reads in hundredths of a millilitre, not in milligrams. Adding 1.0 mL of bacteriostatic water to a 10 mg vial gives 10 mg/mL, so each unit holds 0.1 mg and a 9 mg dose is 90 units in a single draw. Adding 2.0 or 2.5 mL lowers the concentration to 5 or 4 mg/mL, which makes 1 mg doses easier to measure but pushes 6 and 9 mg doses beyond one syringe.
| Research dose | 1.0 mL added (10 mg/mL; 1 unit = 0.1 mg) | 2.0 mL added (5 mg/mL; 1 unit = 0.05 mg) | 2.5 mL added (4 mg/mL; 1 unit = 0.04 mg) |
|---|---|---|---|
| 1 mg | 0.10 mL = 10 units | 0.20 mL = 20 units | 0.25 mL = 25 units |
| 3 mg | 0.30 mL = 30 units | 0.60 mL = 60 units | 0.75 mL = 75 units |
| 6 mg | 0.60 mL = 60 units | 1.20 mL (two draws) | 1.5 mL (two draws) |
| 9 mg | 0.90 mL = 90 units | 1.80 mL (two draws) | 2.25 mL (three draws) |
Arithmetic only: concentration = 10 mg ÷ mL added; volume = dose ÷ concentration; units = mL × 100 on a U-100 syringe. No eloralintide-specific stability data have been published.
For protocols modelled on the Phase 2 range, 1.0 mL is the practical choice because every trial dose then fits one draw of a 1 mL syringe; 2.0 or 2.5 mL suits low-dose work such as 1 mg. The peptide calculator reproduces the table for any other volume, and the calculator walkthrough shows the inputs. Step-by-step technique for this specific vial is in the eloralintide reconstitution guide.

Doses per Vial and Vials per Protocol
Because every Phase 2 eloralintide dosage is a whole number of milligrams, a 10 mg vial divides cleanly at the low end and wastefully at the high end: ten 1 mg doses, three 3 mg doses with 1 mg left, or one 6 mg or 9 mg dose with 4 mg or 1 mg left. Mass is not the only limit, because reconstituted solution is used within about 28 days, so at 1 mg weekly the clock runs out after four doses, not ten. Over a full protocol the remainders add up, which is why the vial counts below are given as exact milligrams first and practical vials second.
| Protocol modelled on the trials | Milligram total | Vials (10 mg each) |
|---|---|---|
| 1 mg weekly | 1 mg per dose | Ten doses by mass, but about four within the 28-day window; one vial per four weeks |
| 3 mg weekly | 3 mg per dose | Three doses per vial, 1 mg left over |
| 6 mg weekly | 6 mg per dose | One dose per vial, 4 mg left over |
| 9 mg weekly | 9 mg per dose | One dose per vial, 1 mg left over |
| 3→6→9 mg over 12 weeks (4 + 4 + 4 weeks) | 12 + 24 + 36 = 72 mg | 7.2 vials; practically 8 |
| Fixed 9 mg over 12 weeks | 108 mg | 10.8 vials; practically 11 |
| 3→6→9 mg over 48 weeks (trial length) | 12 + 24 + 360 = 396 mg | 39.6 vials; practically 40 |
| 6→9 mg over 48 weeks (20 + 28 weeks) | 120 + 252 = 372 mg | 37.2 vials; practically 38 |
| Fixed 9 mg over 48 weeks | 432 mg | 43.2 vials; practically 44 |
Arithmetic only, based on the Phase 2 schedules in Billings et al., The Lancet 2025. “Practically” rounds up to whole vials and assumes each vial’s leftover is drawn together with the next vial inside the 28-day window; drawing every 6 or 9 mg dose from a fresh vial instead takes one vial per dose, or 12 vials for 12 weeks at a fixed 9 mg.
Timing, Injection Site and Storage in a Research Protocol
Every published eloralintide dosage was subcutaneous and once weekly; Lilly’s own page states that in clinical trials the drug “was self-injected once weekly” (Lilly, What to know about eloralintide). With a 1.28–1.38 peak-to-trough ratio at steady state, the seven-day interval matters more than the time of day.
Injection-site reactions were common in Phase 1b, at 13.9% to 33.3% across active arms against 3.7% on placebo, mostly mild, so protocols record the site at each dose and rotate it; our comparison of subcutaneous and intramuscular peptide injection covers the route the trials used.
Storage follows standard lyophilized-peptide handling, since no eloralintide-specific stability data exist: lyophilized vials frozen or refrigerated away from light, reconstituted solution at 2–8 °C and used within about 28 days, with bacteriostatic water as the diluent for multi-dose use. The peptide storage guide is the reference for both states.
The 12 mg Signal: Mood Events Above the Phase 2 Range
The 12 mg weekly dose matters because it sits above anything Lilly carried into Phase 2 and because it produced the mood-related withdrawals described here. In Phase 1b, 11 eloralintide participants discontinued for adverse events, including two cases of depressed mood, one of persistent depressive disorder, one of somnolence and one of decreased appetite; all three mood-related withdrawals occurred in the 12 mg cohort and resolved within 2 to 4 days, with one additional mild depressed-mood event at 6 mg (Bhattachar et al. 2026).
The single serious adverse event on drug, an acute kidney injury at 6 mg, was judged unrelated, and nobody left the study for nausea, vomiting or diarrhoea. In the single-dose study, every GI event and the only injection-site reaction likewise sat in the 12 mg cohort. The practical reading for any eloralintide dosage protocol is that the published efficacy range tops out at 9 mg, and that 12 mg has 12 weeks of data in 36 people, not 48 weeks in a Phase 2 arm.
Common Dosing Errors and How the Data Correct Them
| Error | Why it is wrong | What the record shows |
|---|---|---|
| Quoting four-week steps for every escalation arm | Only the 3→6→9 mg arm used four-week steps | 6→9 mg arm: 6 mg for 20 weeks, then 9 mg for 28 weeks (Billings et al. 2025) |
| Listing 12 mg as a Phase 2 dose | 12 mg appears only in the single-dose study and the 12-week Phase 1b study | Highest Phase 2 dose 9 mg; highest EloraTZP eloralintide dose 9 mg |
| Mixing the two Phase 2 estimands | −20.1% and −17.5% describe the same 9 mg arm under different rules | Efficacy estimand −20.1%; treatment-regimen estimand −17.5% |
| Confusing syringe units with milligrams | Units depend on concentration | At 10 mg/mL, 30 units = 3 mg; at 5 mg/mL, 30 units = 1.5 mg |
| Assuming steady state after two or three weeks | Half-life is about 14 days | Steady state after roughly 2–2.5 months; effects persisted 9–10 weeks after the last dose |
| Comparing EloraTZP eloralintide-alone arms with Phase 2 | EloraTZP enrolled people with type 2 diabetes | Alone arms −8.2% to −12.3% in T2D versus −12.4% to −20.1% without T2D at matching doses |
| Starting at a fixed high dose and expecting slow-escalation tolerability | Nausea tracked both dose and speed | Fixed 6 mg 64.3% nausea; 3→6→9 mg 25.0% |
Sources: Billings et al., The Lancet 2025; Lilly press release, Nov 6, 2025; Bhattachar et al., Diabetes, Obesity and Metabolism 2026; Lilly press release, Sept 30, 2026; vial arithmetic as above.
A softer but common error is treating the treatment-regimen estimand as a “real-world” number and the efficacy estimand as inflated. Both are legitimate analyses of the same arm; the first keeps people who stopped dosing and the second does not, and an eloralintide dosage comparison is only honest when it names which one it is using.

The 10 mg Eloralintide Vial at PSPeptides
PSPeptides supplies eloralintide as a single 10 mg lyophilized vial, which maps directly onto the Phase 2 eloralintide dosage range: one vial per 9 mg research dose, or four 1 mg doses inside the 28-day window for low-dose designs. Each lot is synthesized in a cGMP-compliant facility in Temecula, California and tested by independent accredited laboratories for HPLC purity (99%+ minimum) and mass-spectrometry identity, plus endotoxin, sterility, heavy-metal and fentanyl screening, as set out on the certifications page.
The eloralintide product page carries current pricing and publishes each lot’s batch-specific certificate of analysis; bacteriostatic water and U-100 insulin syringes are stocked alongside it, so everything goes in one order. Orders placed before 2 PM EST ship the same day, US shipping is free, and cards, Afterpay and Klarna are accepted.
Order eloralintide 10 mg — pricing and the lot COA are on the product page.
Frequently Asked Questions About Eloralintide Doses
How many units is 3 mg of eloralintide from a 10 mg vial?
It depends on the reconstitution volume. With 1.0 mL of bacteriostatic water the vial is 10 mg/mL, so 3 mg is 0.30 mL, or 30 units on a U-100 insulin syringe; with 2.0 mL it is 60 units, and with 2.5 mL it is 75 units.
What was the highest eloralintide dose studied?
The highest eloralintide dosage given to humans was 12 mg, as a single injection in the Phase 1 study and as a weekly dose for 12 weeks without titration in the Phase 1b study. The highest Phase 2 dose was 9 mg weekly, and the EloraTZP trial also capped eloralintide at 9 mg.
How long does one 10 mg vial last at the Phase 2 doses?
By mass a 10 mg vial holds ten 1 mg doses, three 3 mg doses with 1 mg left over, or a single 6 mg or 9 mg dose, but reconstituted solution is used within about 28 days, so at 1 mg weekly one vial covers about four doses. A 12-week eloralintide dosage protocol modelled on the 3→6→9 mg arm uses 72 mg, about eight vials, while 12 weeks at a fixed 9 mg uses 108 mg, 11 vials if leftovers are combined with the next vial or 12 if every dose comes from a fresh one.
Did the Phase 2 trial escalate every arm in four-week steps?
No. Only the 3→6→9 mg arm used four-week steps, taking 3 mg for four weeks and 6 mg for four weeks before 40 weeks at 9 mg. The 6→9 mg arm stayed at 6 mg for 20 weeks before moving to 9 mg for the final 28 weeks, and the 1, 3, 6 and 9 mg arms were fixed throughout.
Why is eloralintide given once a week?
Its terminal half-life was 310 to 366 hours, roughly 13 to 15 days, after single doses, and about 14 days with repeated weekly dosing, which produced relatively flat weekly concentrations with a peak-to-trough ratio of 1.28 to 1.38. The Phase 1 authors concluded that this profile supports once-weekly dosing.
References
- Billings LK, Hsia S, Bays H, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. 2025;406(10520):2631–2643. https://doi.org/10.1016/S0140-6736(25)02155-5
- Eli Lilly press release, Nov 6, 2025 — “Lilly’s selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight.” https://investor.lilly.com/node/53246
- Bhattachar S, Tham LS, Tidemann-Miller B, et al. Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes, Obesity and Metabolism. 2026;28(4):2651–2660. https://doi.org/10.1111/dom.70439
- Briere DA, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Molecular Metabolism. 2025;102:102271. https://doi.org/10.1016/j.molmet.2025.102271
- Eli Lilly press release, Sept 30, 2026 — “Lilly’s EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction…” https://investor.lilly.com/news-releases/news-release-details/lillys-eloratzp-combination-eloralintide-and-tirzepatide
- Eli Lilly, “What to know about eloralintide” (last updated September 2026). https://www.lilly.com/news/stories/what-to-know-about-eloralintide
All PSPeptides products are sold exclusively for research and laboratory use.